{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:55:24Z","timestamp":1790837724909,"version":"4.1.0"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>In recent years, advances in the understanding of idiopathic inflammatory myopathies (IIM) pathogenesis have led to the development of targeted therapies directed against key immune pathways. This review highlights recent advances in clinical trials, emerging therapeutic strategies, and the rapidly evolving treatment landscape in IIM, reflecting the continued expansion of the therapeutic armamentarium.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Multiple clinical trials have evaluated therapeutics directed against key immune pathways implicated in IIM, including B-cell depletion, T-cell co-stimulation, type I interferon (IFN) signaling, fragment crystallizable receptor (FcRn) inhibition and Janus kinase (JAK) \/STAT blockade. Promising results have been reported with agents such as JAK inhibitors, FcRn antagonists, anti-IFN therapies, and chimeric antigen receptor (CAR) T-cell approaches in selected patients. Several additional experimental trials are ongoing to evaluate novel therapeutic agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Several recent landmarks clinical trials in IIM suggest that targeted therapies directed at key immune pathways may improve disease control beyond conventional immunosuppression, supporting a shift toward mechanism-based treatment approaches in clinical practice. The rapid and expanding growth of clinical studies in IIM reflects an unprecedented acceleration in therapeutic development, underscoring the progress in the field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001189","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:00:06Z","timestamp":1787727606000},"page":"488-498","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The current clinical trial landscape in idiopathic inflammatory myopathies"],"prefix":"10.1097","volume":"38","author":[{"given":"Nikola","family":"Wilk","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, The Ottawa Hospital"},{"name":"Faculty of Medicine, University of Ottawa"},{"name":"Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Paik","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrilee","family":"Needham","sequence":"additional","affiliation":[{"name":"University of Notre Dame Australia, Fremantle"},{"name":"Institute of Immunology and Infectious Diseases, Murdoch University"},{"name":"Department of Neurology, Fiona Stanley Hospital, Murdoch"},{"name":"Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Chinoy","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester"},{"name":"Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","article-title":"Epidemiology of the idiopathic inflammatory myopathies","volume":"19","author":"Khoo","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"R2-20261001","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0889-857X(02)00023-6","article-title":"Clinical presentation of the idiopathic inflammatory myopathies","volume":"28","author":"Yazici","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/mus.28050","article-title":"Positive predictive value of myositis antibody line blot testing in patients with suspected idiopathic inflammatory myopathy","volume":"69","author":"Chang","year":"2024","journal-title":"Muscle Nerve"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7861\/clinmedicine.17-4-322","article-title":"Idiopathic inflammatory myopathies \u2013 a guide to subtypes, diagnostic approach and treatment","volume":"17","author":"Oldroyd","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"R5-20261001","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/annrheumdis-2017-211402","article-title":"Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study","volume":"77","author":"Dobloug","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jaad.2025.06.062","article-title":"The Prospective Registry Of MyositIS (PROMIS). II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies","volume":"93","author":"Yu","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00296-017-3799-x","article-title":"Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain","volume":"37","author":"Nuno-Nuno","year":"2017","journal-title":"Rheumatol Int"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.1987.03400040111034","article-title":"Reversal of chronic polymyositis following intravenous immune serum globulin therapy","volume":"258","author":"Roifman","year":"1987","journal-title":"JAMA"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11926-023-01105-w","article-title":"Intravenous immunoglobulin in idiopathic inflammatory myopathies: a practical guide for clinical use","volume":"25","author":"Gandiga","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"R11-20261001","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/rheumatology\/keaa459","article-title":"Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study","volume":"60","author":"Lim","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"e23677","DOI":"10.1097\/MD.0000000000023677","article-title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u201cProDERM Study\u201d)","volume":"100","author":"Aggarwal","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"R14-20261001","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40744-025-00775-5","article-title":"Efficacy of intravenous immunoglobulin for systemic manifestations of dermatomyositis beyond muscular and cutaneous: sub-analysis of the ProDERM Study","volume":"12","author":"Aggarwal","year":"2025","journal-title":"Rheumatol Ther"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"e067435","DOI":"10.1136\/bmjopen-2022-067435","article-title":"Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial","volume":"13","author":"Kamperman","year":"2023","journal-title":"BMJ Open"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMra2415426","article-title":"Inflammatory myopathies","volume":"394","author":"Allenbach","year":"2026","journal-title":"N Engl J Med"},{"key":"R18-20261001","article-title":"Efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy: phase 2 results from the ALKIVIA study","author":"Chinoy","year":"2025","journal-title":"EULAR Congress 2025 Barcelona, Spain: Annals of the Rheumatic Diseases"},{"key":"R19-20261001","doi-asserted-by":"crossref","first-page":"1560483","DOI":"10.3389\/fneur.2025.1560483","article-title":"Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy","volume":"16","author":"Peng","year":"2025","journal-title":"Front Neurol"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"1447182","DOI":"10.3389\/fimmu.2024.1447182","article-title":"Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"R21-20261001","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"R22-20261001","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med"},{"key":"R23-20261001","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R24-20261001","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"R25-20261001","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R26-20261001","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.41944","article-title":"Long-term extension study of tofacitinib in refractory dermatomyositis","volume":"74","author":"Paik","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R27-20261001","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.semarthrit.2016.08.009","article-title":"A case of refractory dermatomyositis responsive to tofacitinib","volume":"46","author":"Paik","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2021.07.003","article-title":"Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers","volume":"86","author":"Min","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R29-20261001","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2503531","article-title":"A phase 3 trial of brepocitinib in dermatomyositis","volume":"394","author":"Vleugels","year":"2026","journal-title":"N Engl J Med"},{"key":"R31-20261001","doi-asserted-by":"crossref","first-page":"e089827","DOI":"10.1136\/bmjopen-2024-089827","article-title":"Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behcet's disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol","volume":"15","author":"Geertsema-Hoeve","year":"2025","journal-title":"BMJ Open"},{"key":"R32-20261001","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R33-20261001","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","article-title":"Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Fiorentino","year":"2025","journal-title":"Lancet"},{"key":"R34-20261001","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3899\/jrheum.2025-0773","article-title":"Anifrolumab therapy in dermatomyositis: new insights from refractory patients","volume":"53","author":"Carli","year":"2026","journal-title":"J Rheumatol"},{"key":"R35-20261001","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1093\/rheumatology\/keaf388","article-title":"Improvement of recalcitrant multisystem disease in dermatomyositis with anifrolumab: a case series","volume":"64","author":"Patel","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R36-20261001","doi-asserted-by":"crossref","first-page":"keaf662","DOI":"10.1093\/rheumatology\/keaf662","article-title":"Real-world experience of anifrolumab in 30 patients with refractory DM: a multicentre-multidisciplinary retrospective study","volume":"65","author":"Retuerto-Guerrero","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"R37-20261001","first-page":"5560523","article-title":"Anifrolumab in refractory dermatomyositis and antisynthetase syndrome","volume":"2025","author":"Soares","year":"2025","journal-title":"Case Rep Rheumatol"},{"key":"R38-20261001","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R39-20261001","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R40-20261001","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/rheumatology\/kead281","article-title":"Belimumab treatment of adult idiopathic inflammatory myopathy","volume":"63","author":"Marder","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R41-20261001","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41577-025-01141-w","article-title":"Defining immune reset: achieving sustained remission in autoimmune diseases","volume":"25","author":"Junt","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"R42-20261001","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41584-026-01357-7","article-title":"Immune reset and immune retune: approaching cure?","volume":"22","author":"Isaacs","year":"2026","journal-title":"Nat Rev Rheumatol"},{"key":"R43-20261001","doi-asserted-by":"crossref","first-page":"100677","DOI":"10.1016\/j.medj.2025.100677","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"R45-20261001","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"Muller","year":"2023","journal-title":"Lancet"},{"key":"R46-20261001","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2013 a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"R47-20261001","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"Muller","year":"2025","journal-title":"Nat Med"},{"key":"R48-20261001","doi-asserted-by":"crossref","first-page":"104060","DOI":"10.1016\/j.autrev.2026.104060","article-title":"Bispecific T-cell engagers in autoimmune diseases: mechanisms of action, clinical evidence challenges, and therapeutic perspectives","volume":"25","author":"Larue","year":"2026","journal-title":"Autoimmun Rev"},{"key":"R49-20261001","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"R50-20261001","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMc2506740","article-title":"BCMA T-cell engager therapy in patients with refractory autoimmune disease","volume":"393","author":"Bucci","year":"2025","journal-title":"N Engl J Med"},{"key":"R51-20261001","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/clim.1999.4743","article-title":"Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells","volume":"92","author":"Nagaraju","year":"1999","journal-title":"Clin Immunol"},{"key":"R52-20261001","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tjarnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R53-20261001","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/art.43066","article-title":"Efficacy and safety of subcutaneous abatacept plus standard treatment for active idiopathic inflammatory myopathy: phase 3 randomized controlled trial","volume":"77","author":"Aggarwal","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"(SI)","key":"R54-20261001","doi-asserted-by":"crossref","first-page":"SI156","DOI":"10.1093\/rheumatology\/keaf218","article-title":"Abatacept for the treatment of myositis-associated interstitial lung disease","volume":"64","author":"Aggarwal","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R55-20261001","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/bioengineering10020176","article-title":"Hematopoietic stem cell transplantation for the treatment of autoimmune neurological diseases: an update","volume":"10","author":"Mariottini","year":"2023","journal-title":"Bioengineering (Basel)"},{"key":"R56-20261001","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2141.2000.02191.x","article-title":"Effective treatment of Jo-1-associated polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation","volume":"110","author":"Baron","year":"2000","journal-title":"Br J Haematol"},{"key":"R57-20261001","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/03009740903096622","article-title":"Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis","volume":"39","author":"Holzer","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"R58-20261001","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12969-018-0284-3","article-title":"Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: a case-series study","volume":"16","author":"Zhu","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"R59-20261001","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ard.2024.11.005","article-title":"Mitochondrial transplantation as a novel therapeutic approach in idiopathic inflammatory myopathy","volume":"84","author":"Kim","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R60-20261001","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2020.07.122","article-title":"A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7\/8\/9 antagonist, IMO-8400, in dermatomyositis","volume":"84","author":"Kim","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R61-20261001","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40744-021-00301-3","article-title":"Treatment of active idiopathic inflammatory myopathies by low-dose interleukin-2: a prospective cohort pilot study","volume":"8","author":"Miao","year":"2021","journal-title":"Rheumatol Ther"},{"key":"R62-20261001","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1038\/s41598-018-23539-4","article-title":"Interleukin-23 as a therapeutic target for inflammatory myopathy","volume":"8","author":"Umezawa","year":"2018","journal-title":"Sci Rep"},{"key":"R63-20261001","doi-asserted-by":"crossref","first-page":"e003268","DOI":"10.1136\/rmdopen-2023-003268","article-title":"Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments","volume":"9","author":"Kawahata","year":"2023","journal-title":"RMD Open"},{"key":"R64-20261001","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jdcr.2018.11.019","article-title":"Apremilast as a potential treatment for moderate to severe dermatomyositis: a retrospective study of 3 patients","volume":"5","author":"Bitar","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"(8S)","key":"R65-20261001","doi-asserted-by":"crossref","first-page":"S561","DOI":"10.1097\/RHU.0000000000000999","article-title":"Refractory cutaneous dermatomyositis with severe scalp pruritus responsive to apremilast","volume":"27","author":"Charlton","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"R66-20261001","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jamadermatol.2022.3917","article-title":"Apremilast in recalcitrant cutaneous dermatomyositis: a nonrandomized controlled trial","volume":"158","author":"Bitar","year":"2022","journal-title":"JAMA Dermatol"},{"key":"R67-20261001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/JND-230168","article-title":"Contribution of complement, microangiopathy and inflammation in idiopathic inflammatory myopathies","volume":"11","author":"Honda","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"(Suppl 9)","key":"R68-20261001","article-title":"RAY121, a novel recycling monoclonal antibody against complement C1s: safety, pharmacokinetic and pharmacodynamic data from a phase 1a first in human clinical trial in healthy adults","volume":"76","author":"Haranaka","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R69-20261001","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.nut.2017.06.023","article-title":"Intake of omega-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"45","author":"Gioxari","year":"2018","journal-title":"Nutrition"},{"key":"R70-20261001","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/09612033211067985","article-title":"The effect of Omega-3 fatty acid supplementation in systemic lupus erythematosus patients: a systematic review","volume":"31","author":"Ramessar","year":"2022","journal-title":"Lupus"},{"issue":"(Suppl 9)","key":"R72-20261001","article-title":"Zetomipzomib demonstrates favorable long-term safety and tolerability profile without signs of immunosuppression: results from the PRESIDIO study and its open-label extension study in patients with dermatomyositis and polymyositis [abstract]","volume":"75","author":"Aggarwal","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R73-20261001","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/BOR.0b013e32834ff5cd","article-title":"Soft tissue and subcutaneous calcification in connective tissue diseases","volume":"24","author":"Chander","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"R74-20261001","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.semarthrit.2005.01.016","article-title":"Calcinosis in rheumatic diseases","volume":"34","author":"Boulman","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"R75-20261001","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2017.3758","article-title":"Factors associated with clinical remission of skin disease in dermatomyositis","volume":"154","author":"Wolstencroft","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R76-20261001","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/ard-2023-224652","article-title":"Current myositis clinical trials and tribulations","volume":"83","author":"Saygin","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R77-20261001","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1038\/s41591-025-03899-x","article-title":"Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Wang","year":"2025","journal-title":"Nat Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:02:44Z","timestamp":1790834564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001189","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}